Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | FBP1 | P09467 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10515945 | 0.73 | CYP2A6 (0.39) | CYP2A6KDM4EALDH1A1SMN1; SMN2HTT | |
| SCHEMBL28777077 | 0.73 | CYP2A6 (0.39) | CYP2A6KDM4EALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL28597830 | 0.73 | KDM4E (0.40) | CYP2A6KDM4EALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL5472442 | 0.72 | CYP2A6 (0.49) | CYP2A6KDM4EALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL28596221 | 0.72 | SMN1; SMN2 (0.37) | CYP2A6KDM4EALDH1A1SMN1; SMN2HTT | |
| SCHEMBL296899 | 0.71 | MAPK1 (0.42) | KDM4EALDH1A1SMN1; SMN2LMNAGLA | |
| SCHEMBL28596244 | 0.70 | KDM4E (0.38) | CYP2A6KDM4EALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL1196464 | 0.70 | CYP19A1 (0.39) | CYP2A6KDM4EALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL289744 | 0.69 | CYP2A6 (0.46) | CYP2A6KDM4EALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL184324 | 0.69 | NOTUM (0.52) | KDM4EALDH1A1LMNAHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 185 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339904-A1 | ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2023-10-26 | — | — | US | claimed |
| US-RE48841-E1 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2021-12-07 | — | — | US | claimed |
| CN-113164459-A | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2021-07-23 | — | — | CN | claimed |
| US-11059828-B2 | Disubstituted octahydropyrrolo[3,4-C]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2021-07-13 | — | — | US | claimed |
| EP-3107898-B1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICALS CO (JP) | 2021-01-06 | — | — | EP | claimed |
| US-10689373-B2 | 1,2-substituted cyclopentanes as orexin receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-06-23 | — | — | US | claimed |
| US-20200048263-A1 | Disubstituted Octahydropyrrolo[3,4-C]Pyrroles As Orexin Receptor Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-02-13 | — | — | US | claimed |
| EP-3093291-B1 | DISUBSTITUTED OCTAHY - DROPYRROLO [3,4-C]PYRROLES AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-05-08 | — | — | EP | claimed |
| US-20180282309-A1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-04 | — | — | US | claimed |
| US-10011588-B2 | 1,2-substituted cyclopentanes as orexin receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-07-03 | — | — | US | claimed |
| US-7507732-B2 | Cyclopentapyridine and tetrahydroquinoline derivatives | PFIZER INC. (US) | 2009-03-24 | — | — | US | claimed |
| US-20090069284-A1 | Substituted 3-alkyl and 3-alkenyl azetidine derivatives | MERCK SHARP & DOHME CORP. | 2009-03-12 | — | — | US | claimed |
| EP-1972631-A1 | Imidazopyridazines as PI3K lipid kinase inhibitors | Novartis AG (CH) | 2008-09-24 | — | — | EP | claimed |
| WO-2008037477-A1 | PYRAZOLOPYRIMIDINES AS P13K LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-04-03 | — | — | WO | claimed |
| EP-0335636-A1 | Antiviral compounds | SYNPHAR LABORATORIES INC. (CA) | 1989-10-04 | — | — | EP | claimed |
| EP-0023026-B1 | MIXTURES OF OPTICAL BRIGHTENERS AND THEIR USE | HOECHST AKTIENGESELLSCHAFT (DE) | 1984-02-22 | — | — | EP | claimed |
| EP-0023028-B1 | MIXTURES OF OPTICAL BRIGHTENERS AND THEIR USE | HOECHST AKTIENGESELLSCHAFT (DE) | 1982-12-15 | — | — | EP | claimed |
| US-4336155-A | CYANOSTYRYL COMPOUNDS AND OTHER BRIGHTENER | HOECHST AKTIENGESELLSCHAFT (DE) | 1982-06-22 | — | — | US | claimed |
| US-4330427-A | Mixtures of optical brighteners | HOECHST AKTIENGESELLSCHAFT (DE) | 1982-05-18 | — | — | US | claimed |
| EP-0023026-A1 | Mixtures of optical brighteners and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-01-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180282309-A1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR1, HCRTR2, NPY1R | CYP2A6 867/4885KDM4E 1117/4885ALDH1A1 570/4885 |
| US-20230339904-A1 | ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | CSNK1A1, CSNK1D, CSNK1G1 | CYP2A6 1127/4885KDM4E 4330/4885ALDH1A1 1318/4885 |
| US-10011588-B2 | 1,2-substituted cyclopentanes as orexin receptor antagonists | HCRTR1, HCRTR2, NPY1R | CYP2A6 854/4885KDM4E 1154/4885ALDH1A1 552/4885 |
| US-20200048263-A1 | Disubstituted Octahydropyrrolo[3,4-C]Pyrroles As Orexin Receptor Modulators | HCRTR2, HCRTR1, OXTR | CYP2A6 2771/4885KDM4E 454/4885ALDH1A1 3132/4885 |
| US-20090069284-A1 | Substituted 3-alkyl and 3-alkenyl azetidine derivatives | CNR1, CNR2, MAG | CYP2A6 598/4885KDM4E 1972/4885ALDH1A1 2399/4885 |
| US-11059828-B2 | Disubstituted octahydropyrrolo[3,4-C]pyrroles as orexin receptor modulators | HCRTR2, HCRTR1, OXTR | CYP2A6 2771/4885KDM4E 454/4885ALDH1A1 3132/4885 |
| US-10689373-B2 | 1,2-substituted cyclopentanes as orexin receptor antagonists | HCRTR1, HCRTR2, NPY1R | CYP2A6 867/4885KDM4E 1117/4885ALDH1A1 570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.